Jun 15, 2022 / 05:40PM GMT
Madhu Sudhan Kumar - Goldman Sachs Group, Inc., Research Division - Research Analyst
All right. So thanks, everyone, for joining us this morning at the Goldman Sachs Global Healthcare Conference. Really pleased to be joined by Krish from Krystal Biotech to give us an update on where things are, where things are headed. Obviously, it's a really important year for the company. And so thanks for joining us, Krish.
Krish S. Krishnan - Krystal Biotech, Inc. - Founder, Chairman, President & CEO
Thanks for having me.
Questions and Answers:
Madhu Sudhan Kumar - Goldman Sachs Group, Inc., Research Division - Research AnalystGreat. So let's start with the discussion of your lead drug VYJUVEK for dystrophic epidermolysis bullosa, or DEB. So first level, let's start with the kind of straightforward high-level discussion of the mechanism of action of VYJUVEK.
Krish S. Krishnan - Krystal Biotech, Inc. - Founder, Chairman, President & CEO
So yes, so VYJUVEK is a modified
Trustpilot
